Several lines of evidence have shown FBXL10 is overexpressed in many human cancers including acute myeloid leukemia (AML) [27], seminomas [28] and pancreatic ductal adenocarcinomas [29]. This evidence concerns the gene KDM2B and acute myeloid leukemia.